Navigation Links
HeartWare to Present at The Lazard Capital Markets 3rd Annual Circulatory Assist Device Day
Date:9/19/2011

FRAMINGHAM, Mass. and SYDNEY, Sept. 19, 2011 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Lazard Capital Markets 3rd Annual Circulatory Assist Device Day at 1:55 p.m. ET on Thursday, September 22, 2011.  The one-day conference is being held at the Langham Hotel in Boston.

A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com.  A replay of the webcast will be available at the site after the presentation.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® Pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union and TGA approval in Australia.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant and destination therapy.  For additional information, please visit www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

HEARTWARE, HVAD, MVAD and HeartWare logos are registered trademarks of HeartWare, Inc.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864


'/>"/>
SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Presentation of HeartWare Clinical Results
2. HeartWare International Clinical Trial Shows 90% Survival at 180 Days
3. U.S. FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U.S. Bridge-to-Transplant Clinical Trial
4. HeartWare International Reports Third Quarter Revenues of $7.5 Million
5. HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City
6. HeartWare to Present at the UBS 2010 Global Life Sciences Conference
7. HeartWare to Present at Lazard Capital Markets Circulatory Assist Device Day
8. HeartWare to Report Financial Results for Third Quarter of 2010
9. HeartWare International Reports Third Quarter 2010 Revenues of $13.8 Million; Compared to $7.5 Million in Third Quarter of 2009
10. HeartWare Bridge-to-Transplant Data Featured as Late Breaking Clinical Trial at American Heart Association Scientific Sessions 2010
11. HeartWare to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 18, 2017 The Academy of Managed ... Administration (FDA) for its release today of draft ... decision makers can proactively share clinical and economic ... as emerging therapies awaiting FDA approval. ... that AMCP developed during two multi-stakeholder meetings last ...
(Date:1/18/2017)... 2017  EnteroMedics Inc. (NASDAQ: ETRM ... technology to treat obesity, metabolic diseases and other ... underwritten public offering of units for gross proceeds ... and commissions and offering expenses payable by EnteroMedics. ... A Units, priced at a public offering price ...
(Date:1/18/2017)... India , January 18, 2017 ... Imaging Technologies Market by Type: Global Opportunity Analysis and Industry ... size was valued at $2,544 million in 2015 and is ... CAGR of 8.4% from 2016 to 2022. North ... accounted for over three-fourths market share in 2015. Ionizing breast ...
Breaking Medicine Technology:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Doctor C ... it attended the January ECRM trade show to continue the marketing and distribution of ... C supplement, known for providing 400 percent better absorption than traditional vitamin C supplements. ...
(Date:1/20/2017)... ... 2017 , ... International Protein, a company based out of Australia that focuses ... January ECRM trade show in Hilton Head, SC. , International Protein was founded ... a line of products that would elevate her fitness regime. At this ECRM trade ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Mary Magdalene: Grace is Greater than Sin”: ... woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is ... as an educator interacting with countless women who had little knowledge of the female ...
(Date:1/20/2017)... ... January 20, 2017 , ... D R ... Pressure (OPEP) device, was featured in a study indicating superior performance against competitive ... “Analysis of Three Oscillating Positive Expiratory Pressure Devices During Simulated Breathing“ was ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Land of More and More”: a ... world hunger, and shares the simple and achievable answer. “The Land of More and ... the Fairview Missionary Church in Angola, Indiana where he works with the children’s ministry ...
Breaking Medicine News(10 mins):